PSMA is also expressed by a variety of non-prostate cancers, often on the endothelium of tumor-associated neovasculature [5], and initial studies have explored the application of PSMA ligands in breast, lung, bladder, pancreatic and colorectal cancer, renal cell carcinoma, and glioblastoma [6]. Here, FOLH1 is linked to prostate carcinoma.